Rate of Venous Thromboembolism Increased With Cancer Surgery

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 2, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, Feb. 2, 2024 -- The rate of venous thromboembolism is increased in association with cancer surgery, according to a study published online Feb. 2 in JAMA Network Open.

Johan Björklund, M.D., Ph.D., from the Karolinska Institutet in Stockholm, and colleagues examined the one-year risk of venous thromboembolic events after major cancer surgery in a register-based retrospective observational matched cohort study. Patients who underwent major surgery for cancer of the bladder, breast, colon or rectum, gynecologic organs, kidney and upper urothelial tract, lung, prostate, or gastroesophageal tract were matched with cancer-free members of the general population in a 1:10 ratio (432,218 patients with cancer and 4,009,343 cancer-free comparators).

The researchers found that for all cancers, the crude one-year cumulative risk of pulmonary embolism was higher among the cancer surgery population, with absolute risk differences of 2.69, 0.59, 1.57, 1.32, 1.38, 2.61, 2.13, and 0.57 percentage points for bladder cancer, breast cancer, colorectal cancer, gynecologic organ cancer, kidney and upper urinary tract cancer, lung cancer, gastroesophageal cancer, and prostate cancer, respectively. Comparing patients who underwent cancer surgery with matched comparators, the cause-specific hazard ratio for pulmonary embolism peaked just after discharge and plateaued 60 to 90 days later. For all cancers except breast cancer, the hazard ratio was 10 to 30 times higher at 30 days after surgery. The hazards decreased but never reached the level of the comparison cohorts apart from prostate cancer.

"The results highlight the need for individualized venous thromboembolism risk evaluation and prophylaxis regimens for patients undergoing surgery for different cancers," the authors write.

Two authors disclosed ties to the pharmaceutical and medical technology industries.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-02-03 02:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords